Analytical Data
-
Gene name
Cxcl12
- Application
-
Alternative Names
12-O-tetradecanoylphorbol 13-acetate repressed protein 1 ;TPAR1C-X-C motif chemokine 12;Pre-B cell growth-stimulating factor ;PBSFThymic lymphoma cell-stimulating factor ;TLSF
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P40224
-
Expression Region
22-89aa
-
Molecular Weight
12 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CXCL12, also known as stromal cell-derived factor 1 (SDF-1), is a chemokine that plays a crucial role in various physiological and pathological processes, including immune responses, hematopoiesis, and organ development. It is known for its ability to attract leukocytes to sites of injury or inflammation and is also implicated in cancer metastasis, as it can facilitate the migration of tumor cells. The study of CXCL12 recombinant protein has garnered significant attention due to its potential therapeutic applications. Researchers are investigating its use in regenerating damaged tissues, enhancing stem cell homing, and developing cancer immunotherapies. Recombinant CXCL12 is often produced using techniques such as recombinant DNA technology, allowing for the generation of a pure and functional form of the protein. This has enabled in-depth studies into its structure-function relationships, signaling pathways, and interactions with its receptor CXCR4. Understanding these dynamics is vital for exploiting CXCL12 in clinical settings, particularly in the treatment of diseases like cancer and in regenerative medicine. Furthermore, CXCL12's role in the tumor microenvironment highlights its significance in developing targeted therapies that could inhibit cancer progression while promoting healthy immune responses. Overall, the investigation of CXCL12 recombinant protein is positioned at the forefront of translational research, offering insights that may advance both therapeutic strategies and our fundamental understanding of cellular communication in health and disease.
